Physician profile
Luron M Fleming
NPI 1376172502
$61,324.72
in general payments reported to CMS, 2019-2025
33 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,434 · 2022: $2,245 · 2023: $3,142 · 2024: $22K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $20K · Consulting Fee: $15K · Food and Beverage: $9,896 · Travel and Lodging: $9,137 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $20,125.00 |
| Consulting Fee | $15,375.00 |
| Food and Beverage | $9,896.41 |
| Travel and Lodging | $9,137.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $112.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47,555.12 | 2022-2025 | Auvelity |
| Abbvie INC. | $4,497.50 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,402.48 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,317.26 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $1,036.56 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $716.71 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $599.84 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $542.99 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $497.64 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $485.16 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $438.13 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $335.39 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $303.68 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $270.51 | 2021-2025 | Aplenzin |
| Avanir Pharmaceuticals, INC. | $155.06 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $152.44 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Ironshore Pharmaceuticals INC. | $135.58 | 2024 | |
| Biogen, INC. | $125.14 | 2023 | |
| Acadia Pharmaceuticals INC | $110.99 | 2022-2024 | Nuplazid |
| Tris Pharma INC | $108.22 | 2022-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $94.68 | 2021-2025 | Loreev Xr |
| Corium, LLC | $69.58 | 2021-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $58.95 | 2021 | |
| Idorsia Pharmaceuticals US INC | $55.28 | 2023-2024 | Quviviq |
| Gilead Sciences, INC. | $46.28 | 2021 | |
| Noven Therapeutics, LLC | $41.76 | 2025 | Xelstrym |
| Tms Neurohealth Centers INC. | $38.66 | 2025 | Tms Neurohealth Centers INC. |
| Arbor Pharmaceuticals, INC. | $35.73 | 2021 | |
| Eisai INC. | $29.05 | 2021-2022 | |
| Sage Therapeutics, LLC | $24.05 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $18.81 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $12.76 | 2021 | |
| Aytu Biopharma, INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luron Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.